Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026

No. 7 / 2026Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate ...

Assessing Ascendis Pharma (ASND) Valuation After New COACH Trial Data And YUVIWEL Orphan Drug Exclusivity

Ascendis Pharma (NasdaqGS:ASND) is back in focus after new COACH Phase 2 data on its TransCon combination therapy in achondroplasia and the launch of YUVIWEL in the US following FDA orphan drug ...
MM&M

Tariffs, drug pricing and GLP-1 wars dominate pharma’s Q2 earnings

As the pharma industry continues to grapple with policy pressures like tariffs and drug pricing measures, the category’s most recent earnings reports shed some light on how drugmakers are faring and ...

A Look At Astellas Pharma’s Valuation After A Strong Year Of Share Price Gains

What Astellas Pharma’s recent performance tells you now Astellas Pharma (TSE:4503) has drawn investor attention after a period in which the share price delivered double digit total returns over the ...

Assessing Kaken Pharmaceutical’s (TSE:4521) Valuation After Recent Muted Share Price Momentum

How Kaken Pharmaceutical’s Recent Performance Frames the Investment Question Kaken Pharmaceutical (TSE:4521) has drawn attention after recent share price moves, with a 1 day return of 1.08%, a flat ...
PharmiWeb

Impact of U.S. Administration Pharmaceutical Policies: MFN Pricing and Tariff Exemptions Reshaping Global Drug Pricing and Supply Chains

Against the backdrop of an accelerating transformation in the global pharmaceutical industry, policy variables are becoming critical factors influencing drug pricing systems, supply chain structures, ...